Evaluation of recombinant porcine somatotropin on growth performance, carcass characteristics, meat quality, and muscle biochemical properties of Belgian Landrace pigs.

The dose related effects of recombinant porcine somatotropin (rpST) on growth, carcass characteristics, muscle properties, and meat quality were investigated in lean Belgian Landrace finishing pigs. Ninety-six pigs (48 barrows and 48 gilts) were injected daily with either vehicle, 1.5, 3, or 6 mg of rpST from 60 to 97.5 kg live weight. Each treatment group consisted of six pens of four pigs each (two of each sex). Pigs were given ad libitum access to a high-protein (20.4% CP) cereal-based diet. Administration of rpST increased (P less than .05) growth rate (16.3 to 25.4%) and improved (P less than .05) feed efficiency (16.9 to 29.4%). Feed consumption was reduced (12%; P less than .05) only in the 6 mg of rpST group. Liver, kidney, and heart weights were increased (P less than .05) in the 3 and 6 mg of rpST groups. Although the Belgian Landrace pigs are bred for superior carcass quality, rpST further improved (P less than .05) carcass composition at all dose levels as evidenced by a reduction (10 to 50%) in a number of subcutaneous fat depth measurements, an increase (10 to 20%) in longissimus muscle area, and an improvement in the lean cut:fat cut ratio. Rate of pH decline in the gluteus and longissimus muscles was similar, but rapid, in all groups (pH after 30 min = 5.74 to 5.94); the ultimate (24 or 72 h) pH was .15 to .2 pH units higher (P less than .05) in the pigs that received the 3 and 6 mg of rpST doses.(ABSTRACT TRUNCATED AT 250 WORDS)

Recombinant porcine somatotropin alters performance and carcass characteristics of heavyweight swine and swine fed alternative feedstuffs.

The efficacy of recombinantly derived porcine somatotropin (rpST) in improving the performance and carcass characteristics of heavyweight finishing pigs was determined. In Study 1, 36 pigs were killed for determination of initial carcass composition at 102 kg, and 36 pigs each were given 0, 1.5, 3, 6, or 9 mg of rpST/d from 102 to 136 kg live weight. Corn-soybean meal diets fed contained 19.8% CP and greater than 1% lysine. Study 2 tested the effects of 3 mg/d on pigs for 4 wk from 84 kg BW fed a corn-soybean meal or a triticale-barley-peas diet. Performance variables (ADG, average daily feed intake [ADFI], and feed efficiency [FE]) were measured weekly. Treatment with rpST increased (P less than .01) ADG and FE and decreased (P less than .01) ADFI in both studies. In Study 1, leaf fat, backfat thickness, belly thickness, and carcass fat were all decreased (P less than .01) linearly by rpST. Loin eye area (LEA), total trimmed lean, and total protein content were increased quadratically (P less than .01). At the 3-mg dose, ADFI, ADG, and FE were 87, 130, and 137% of control, and LEA, backfat, total protein gain, and total fat gain were 107, 80, 136, and 52% of control. Loin eye area was not increased (P greater than .05) in the pigs in Study 2; however, backfat thickness was reduced 16% by rpST (P less than .01). The effects of rpST were the same on both dietary regimens (P greater than .05). These studies demonstrate the effectiveness of rpST in increasing ADG and carcass leanness and improving FE in heavyweight pigs and in pigs fed alternative feedstuffs.

Dose response in growth of pigs injected daily with porcine somatotropin from 57 to 103 kilograms.

Exogenous administration of porcine somatotropin (PST) has been shown to promote growth in the pig; however, dose-response relationships and interactions with PST source and sex for animals taken to market weight have not been established clearly. The present study was conducted to determine the relationship between dosage of pituitary-derived and recombinantly manufactured PST (pPST and rPST) and growth (ADG), structural soundness, gain-to-feed ratio (G/F) and average daily feed intake (ADF). Crossbred barrows (n = 113) and gilts (n = 97) were injected with either saline, 1.5, 3.0, 6.0 or 9.0 mg/d of pPST or rPST from 57 +/- .3 to 103.5 +/- .7 kg live weight. Pigs were housed five per pen and had ad libitum access to an 18% crude protein diet for the duration of the experiment. Response curves for pPST and rPST did not differ (P greater than .20) for ADG, soundness score or ADF. Although regression coefficients for response of G/F to pPST and rPST differed (P = .05), pairwise comparisons of treatment means did not (P greater than .10). Response curves for barrows and gilts did not differ for ADG or soundness (P greater than .05). Averaged over PST source and sex, quadratic dose-responses were detected for ADG, G/F and ADF (P less than .01), but PST had no effect on soundness (P greater than .25). Exponential regression models best described the dose-response relationships, and 6.0 mg.pig-1.d-1 was predicted to result in 95% of maximal achievable response for days to 103.5 kg and G/F. At this dose, pigs were predicted to grow .15 kg/d (20%) faster during the treatment period, reach slaughter weight 11.6 d earlier, consume .56 kg/d (19%) less feed, and have a G/F .095 (36%) greater than controls.

Effects of cimaterol, a beta-adrenergic agonist, on protein metabolism in rats.

Fractional accretion rates of total body 3-methylhistidine containing proteins (actin and myosin) were elevated 40% to 120% in rats fed a high-carbohydrate diet containing 10 or 100 ppm cimaterol for 1 week. Fractional degradation and fractional synthesis rates of these proteins were examined by measuring total body 3-methylhistidine content and urinary excretion of 3-methylhistidine. Consumption of the diet containing 100 ppm cimaterol for 1 week caused a 25% reduction in fractional degradation rates and a concomitant 32% increase in fractional synthesis rates of 3-methylhistidine containing proteins. Effects of cimaterol on fractional accretion, degradation, and synthesis rates of 3-methylhistidine containing proteins diminished after 1 week. Cimaterol failed to influence plasma insulin, triiodothyronine, or corticosterone concentrations. The dramatic increase in accretion of 3-methylhistidine containing proteins observed during the first week rats are fed diets containing cimaterol is caused by reciprocal action on protein degradation and synthesis.

Effects of cimaterol, a beta-adrenergic agonist, on lipid metabolism in rats.

Rats fed a high carbohydrate diet containing 10 or 100 ppm cimaterol for 4 weeks gained 41% to 59% less fat and 70% to 76% more protein than controls, with no major changes in either energy gain or efficiency of energy retention. Effects of cimaterol on lipid metabolism in these rats were assessed. Cimaterol stimulated lipolysis in vivo and in vitro, but failed to influence rates of de novo fatty acid synthesis in either liver or white adipose tissue. Activities of fatty acid synthetase and malic enzyme in these tissues were also unaffected by cimaterol. Cimaterol administered in vivo failed to affect lipoprotein lipase activity in white adipose tissue, but elevated enzyme activity 67% to 75% in the extensor digitorium longus muscle. Lipoprotein lipase activity in the extensor digitorum longus muscle was also elevated by 66% during a 2 hour incubation with 1 mmol/L cimaterol. We conclude that cimaterol selectively stimulates both lipolysis in white adipose tissue and lipoprotein lipase activity in skeletal muscle, to direct energy away from adipose tissue deposition toward skeletal muscle accretion.

Effects of cimaterol on nitrogen retention and energy utilization in lambs.

Fifty-two weaned lambs were used in a comparative slaughter feeding trial and six lambs in a concurrent digestibility trial to investigate the effects of cimaterol on nitrogen retention and energy utilization. Cimaterol (CIM) was administered in the feed at 10 ppm for 90 and 14 d, respectively, in a comparative slaughter feeding trial and in a digestibility trial. No difference was found in dry matter digestibility. Nitrogen retention in the CIM group (739 mg/Wkg.75/d) was greater (P less than .01) than that of the control group (321 mg/Wkg.75/d). This difference was accounted for primarily by reduced nitrogen loss in urine of the CIM group. Cimaterol improved growth rate and feed/gain ratio, although these improvements were only evident during the first 42 d of the 90-d feeding trial. The improvement in growth performance of the CIM group was associated with increased protein gain in the empty body (40.2 g/d, P less than .01) as well as in carcass (26.9 g/d, P less than .01), compared with 30.1 and 14.5 g/d of the control group. Cimaterol decreased (P less than .01) fat gain (91.4 vs 109.9 g/d), total daily energy gain (1.08 vs 1.22 Mcal) and energy gain/kg gain (4.17 vs 5.11 Mcal) compared with the control. Feeding CIM increased (P less than .01) estimated fasting heat production (73 vs 64 Kcal/Wkg.75) and metabolizable energy requirement for maintenance (110.2 vs 92.7 Kcal/Wkg.75) over the control.(ABSTRACT TRUNCATED AT 250 WORDS)

Evaluation of cimaterol for finishing swine including a drug withdrawal period.

One hundred fifty crossbred pigs (55 kg) were allotted by weight, sex and litter to a randomized complete-block design with five dietary treatments, six blocks per treatment and five pigs per pen with sex equalized across treatments. Corn-soybean meal-based diets (.65% lysine) with 0, .25 and .5 mg/kg cimaterol were fed, on an ad libitum basis, to pigs slaughtered at an average pen weight of 104 kg/pig. Drug withdrawal prior to slaughter was 1, 3 and 5 d for pigs fed cimaterol at .25 mg/kg and 1 d for those fed cimaterol at .5 mg/kg of diet. Dietary cimaterol level influenced (quadratic, P less than .01) average daily gain during the first 42 d on test; however, daily feed intake and feed conversion ratio were not affected (P greater than .1). Pigs fed .25 mg/kg cimaterol with a 1-d drug withdrawal had 6.8, 7.7 and 13.5% less 10th rib fat depth and 11.1, 6.1 and 13.3% less P2 fat depth than those subjected to either a 3- or 5-d drug withdrawal or those fed the 0 mg/kg cimaterol diet (control), respectively. Overall, pigs fed cimaterol had 7.9% larger longissimus muscle area and 2.6% more kilograms of muscle than pigs fed the control diet. Cimaterol fed at .5 mg/kg resulted in higher (P less than .05) Warner-Bratzler shear force values and altered the proportion of saturation in some long-chain fatty acids, although the total saturated:unsaturated fat ratio was not affected. Pigs fed no cimaterol had less thaw loss (P less than .05) than did those fed other treatments.(ABSTRACT TRUNCATED AT 250 WORDS)

Effect of cimaterol on sheep adipose tissue lipid metabolism.

Effects of dietary cimaterol (5 mg/kg) on adipose tissue metabolism of wether lambs were studied. Lipogenesis, lipolysis, fatty acid composition and adipocyte size and number were measured. Cimaterol feeding increased lipogenesis; however, this effect was not statistically significant. Insulin (1,000 microU/ml) stimulated lipogenesis of adipose tissue from control sheep. However, this elevated rate was abolished by in vitro cimaterol. Insulin had no stimulatory effect on lipogenesis in cimaterol-fed sheep. Lipolysis was depressed by cimaterol feeding. However, 10(-4) M cimaterol stimulated lipolysis in the adipose tissue from both control and cimaterol-fed sheep. Insulin inhibited stimulated lipolysis in adipose tissue from control sheep but had no effect on the stimulated lipolysis in cimaterol-fed sheep. Mean adipocyte diameter was smaller (from 74 to 70 microns) and adipocyte size distribution also was changed in the cimaterol-fed sheep. Adipocyte number per gram of tissue was not affected by cimaterol. There was a significant increase in percentage of unsaturated fatty acids in adipose tissue from cimaterol-fed sheep. These results indicate that lipogenic and lipolytic responses to insulin and cimaterol in sheep adipose tissue were altered by cimaterol feeding. The carcass fat content decrease in cimaterol-fed sheep may be attributed to the reduction in adipocyte size.

Cimaterol-induced muscle hypertrophy and altered endocrine status in lambs.

The objectives of this study were 1) to determine how cellular growth of skeletal muscle is altered by the repartitioning agent cimaterol and 2) to determine if cimaterol alters endocrine status in association with its repartitioning effects. Thirty Dorset wether lambs were randomly assigned to a pre-treatment baseline group or received 0 or 10 ppm cimaterol in a complete, mixed, high-concentrate diet for 7 or 12 wk. Weights of biceps femoris (BF), semimembranosus (SM) and semitendinosus (ST) muscles were 32.8, 27.1 and 31.5% greater, respectively, in treated lambs at 7 wk, and were 22 to 24% greater at 12 wk. Longissimus (LD) cross-sectional area was 26 and 32% greater at these treatment intervals. Percent type I fibers declined significantly over the course of the experiment in ST, SM and LD, and cimaterol caused a small but significant reduction in percent type I fibers in the ST at 7 and 12 wk. Muscles from lambs fed cimaterol contained 50 and 75% more fibers that exhibited negative staining for phosphorylase activity. Mean cross-sectional area of type I and type II fibers in the combined portions of the ST were 30.4 and 29.3% greater, respectively, in cimaterol-fed lambs after 12 wk, while type I and type II fiber areas in the longissimus were only 13 and 15% greater, respectively. Cimaterol-induced hypertrophy of the ST resulted in both protein and RNA content being 30 to 35% greater (P less than .01) at 7 and 12 wk, while DNA concentration was 22% less (P less than .01) at 7 wk. DNA concentration returned to normal by 12 wk. These results indicate that cimaterol elicits a rapid increase in muscle RNA and protein accretion without concurrent incorporation of satellite cell nuclei. Plasma insulin and insulin-like growth factor-1 (IGF-1) concentrations were 55 and 34% lower, respectively, in cimaterol-fed lambs. Plasma somatotropin concentration and area under the curve were 2.3 times greater (P less than .01) in lambs fed cimaterol for 6 wk, while plasma cortisol, prolactin and glucose concentration were unaffected at 6 or 12 wk. The significant changes in endocrine status may be important in the mechanism(s) of cimaterol in altering muscle accretion.

Effect of the repartitioning agent cimaterol on growth, carcass and skeletal muscle characteristics in lambs.

Ten crossbred (Suffolk X Rambouillet) whether lambs were randomly assigned to receive 0 or 10 ppm cimaterol (CIM) in a completely mixed high-concentrate diet for 8 wk. Total weight gain and feed efficiency were improved 29% (P less than .05) and 14%, respectively, in the CIM-fed group. CIM also improved (P less than .01) dressing percent by 4.9 percentage points and improved yield grade by one grade. CIM increased longissimus muscle (LD) area 38% (P less than .01) and the yield of four lean cuts 28% (P less than .01). No difference was found in the proportion of type I (slow-contracting, oxidative) and type II (fast-contracting, mixed glycolytic/oxidative) fibers in LD and semitendinosus (ST) muscles between control and CIM groups, indicating no change in fiber type. The cross-sectional area of type II fibers in LD and ST muscles of the CIM group was 2,081 and 1,951 micron 2 as compared with 1,391 and 1,296 micron2 of the control group, respectively. The increase was approximately 50% (P less than .01). No difference was found in cross-sectional area of type I fibers, indicating that the increase of muscle mass was due to hypertrophy of type II fibers only. DNA concentration (micrograms/g wet muscle or microgram/g protein) of CIM muscle was much lower (P less than .01) than that of control muscle, suggesting that the protein accretion in muscle was accomplished without additional incorporation of nuclei from satellite cells.

Evaluation of feet and skeletons of limbs from pigs treated with a repartitioning agent, cimaterol.

Recently, beta-adrenergic agents, which repartition muscle and fat, have been used to develop more muscular carcasses in broilers, steers, lambs, and pigs. Cimaterol, one such repartitioning agent, effectively improves carcass quality in pigs. Since the mode of action of repartitioning agents is uncertain, and because they may indirectly affect skeletal development or the integrity of feet, the purpose of this study was to assess the effect of cimaterol on selected growth cartilages and feet. Pigs were randomly placed in four groups and fed a ration that included Cimaterol at 0.00, 0.25, 0.50, or 1.00 mg/kg. At 100 kg live-weight, pigs were slaughtered and selected growth cartilages, bones, and feet were examined macroscopically, radiologically, and microscopically. Although the majority of pigs had lesions in feet, or had dyschondroplastic changes typical of osteochondrosis in many growth cartilages, particularly physes, there were no significant differences in frequency of pigs with lesions between groups. Cimaterol enhanced carcass quality with no detrimental effect on bones or feet.

Effect of the beta-adrenergic agonist cimaterol (CL 263,780) on the growth and carcass characteristics of finishing swine.

A randomized complete-block design was used to evaluate the effects of the beta-adrenergic agonist, cimaterol (CL 263,780), on growth rate, feed efficiency and carcass composition of finishing swine. The drug was fed at four levels (0, .25, .5 and 1.0 ppm) to a total of 240 pigs from 64.5 to 103.7 kg live weight. Growth rate and feed efficiency were measured during the 7-wk feeding trial. Feeding cimaterol depressed feed intake, improved feed efficiency and did not alter rate of gain. Carcass evaluation showed that pigs continuously fed cimaterol had 13.2, 9.3 and 9.2% less fat measured at the 10th rib, P2 and average backfat (BF) locations, respectively, compared with controls. Cimaterol-fed pigs had increased loin eye areas (10.9%), and increased semitendinosus (11.8%) and biceps femoris (8.9%) weights compared with controls. The semitendinosus muscles of the cimaterol-fed pigs had less fat and the femur bones were shorter and lighter weight than controls. There were no detected differences in structural soundness of the live pigs, but postmortem evaluation of the hooves indicated that pigs fed 1.0 ppm cimaterol had a higher incidence of hoof lesions. Pigs withdrawn from cimaterol for 7 d were comparable in performance and carcass characteristics with those continuously fed the drug except that carcass fat measurements had generally returned to control values. The data indicate that cimaterol improved the feed efficiency of finishing pigs and increased the lean:fat ratio of their carcasses. Withdrawal of cimaterol caused compensatory fat deposition.

A repartitioning agent to improve performance and carcass composition of broilers.

Clenbuterol [benzyl alcohol, 4-amino-alpha-(t-butylamino)methyl-3,5-dichloro] was tested in the finisher ration of broilers in three series of experiments for its effects on performance and carcass characteristics. In Experiment 1, administration of clenbuterol at feed levels of .25, .5, 1, 2, and 4 ppm from 28 to 49 days of age resulted in significant sex combined weight gain improvements at all levels except 4 ppm and significant feed efficiency improvements at all levels tested. Uneviscerated body composition analysis indicated that clenbuterol treatment significantly increased body protein and water content and decreased body fat in female birds. In males, body fat was significantly reduced by 1, 2, and 4 ppm clenbuterol. From these results the 1 ppm level was selected for further testing. In Experiments 2 and 3, clenbuterol fed from 28 to 49 days of age significantly improved sex combined weight gain and feed efficiency and both male and female 49-day weights. Carcass yield was significantly increased in males and females by 1.11 and 1.91 percentage points, respectively. Abdominal fat was significantly reduced by clenbuterol feeding only in females. Carcass analysis indicated that clenbuterol-fed birds had a significantly lower carcass fat content. In Experiments 4 to 7, clenbuterol was administered at 1 ppm in the finishing feed but was withdrawn 3 to 5 days prior to terminal performance and carcass evaluations. Clenbuterol significantly improved sex combined weight gain and feed efficiency, and 49-day weights for both sexes. Carcass yield was significantly increased in males and females by .54 and .98 percentage points, respectively.(ABSTRACT TRUNCATED AT 250 WORDS)

Postmorten glycolysis in ground skeletal muscle as influenced by prerigor freezing and subsequent thawing.

Ground bovine longissimus and rabbit white muscles were frozen (-25 degrees C) in the prerigor state and subsequently thawed(+20 degrees C) to determine the combined effect of grinding and freezing on glycolytic metabolites and enzymes. Frozen ground muscle, when compared to unfrozen ground tissue, showed significantly lower hexose monophosphates and significantly greater levels of all metabolites from fructose diphosphate to phosphoenolpyruvate, indicating activation of phosphofructokinase and inhibition of pyruvate kinase during the freezing process. Thawing caused rapid glycolysis and the metabolites returned to near unfrozen levels by the time glycolysis ceased, due to strong activation of phosphorylase by Ca2+. Both muscle types had a similar pattern of changes.